As you apply BLS and ALS protocols, this case is a reminder tothoroughly, thoughtfullyand compassionately assess and treat ...

The Newly Launched MicronJet 800 Extends the Portfolio into Hair Restoration as well as Thicker Skin Areas and Viscous ...

Elucid today announced that, effective January 1, 2026, its Plaque-IQtm coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly ...

STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Despite longstanding guidelines, many dementia patients are still prescribed brain-altering medications that can raise the ...

Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production ...

Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production, a process that fails in amyotrophic lateral sclerosis (ALS).

The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of neurodegenerative diseases.According to a press release from VectorY ...